Nephrol Dial Transplant (2003) 18: II2-II6
© 2003 European Renal Association-European Dialysis and Transplant Association
Original Article
Anaemia management prior to dialysis: cardiovascular and cost-benefit observations
University of Minnesota, Minneapolis, MinnesotaUSA
Anaemia correction with recombinant human erythropoietin (rh-EPO, epoetin) in end-stage renal disease (ESRD) patients has been associated with improved survival and quality of life, as well as lower overall treatment costs. Few studies, however, have evaluated the benefits of epoetin treatment given to chronic kidney disease (CKD) patients during the pre-dialysis period. A retrospective study of 89 193 incident haemodialysis patients in the Medicare system (age 
67 years) assessed consistency of epoetin treatment before the start of dialysis and the outcome of patients once they reached ESRD. Patients were grouped according to consistency of epoetin treatment based on the available months of treatment in the 2-year period before starting dialysis. Only 15.6% of patients in the study received any epoetin before the initiation of dialysis. Patients who received no or infrequent epoetin (i.e. received epoetin in <50% of possible months) had a significantly higher relative risk of cardiac disease and death than patients treated with epoetin more frequently. Patients who received no or infrequent epoetin also had significantly higher rates of hospitalization and overall treatment costs at the time of initial dialysis. These findings suggest that early epoetin treatment warrants further investigation in prospective, randomized studies. In summary, it is evident that the care of CKD patients can be improved. Evidence suggests that timely initiation of epoetin treatment to correct renal anaemia appears to be associated with improved survival of ESRD patients in the first year after start of dialysis and reduced costs of treatment.
Keywords: anaemia; chronic kidney disease; cost-benefit; epoetin; haematocrit
Correspondence and offprint requests to: Allan J. Collins MD FACP, Minneapolis Medical Research Foundation, University of Minnesota, 914 South Eighth Street, Suite D-206, Minneapolis, MN 55404, USA. E-mail: acollins{at}nephrology.org
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 F. W Maddux, S. Shetty, M. A del Aguila, M. A Nelson, and B. M Murray Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease Ann. Pharmacother., November 1, 2007; 41(11): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lefebvre, M. S. Duh, S. Buteau, B. Bookhart, and S. H. Mody Medical Costs of Untreated Anemia in Elderly Patients with Predialysis Chronic Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3497 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Drueke, F. Locatelli, N. Clyne, K.-U. Eckardt, I. C. Macdougall, D. Tsakiris, H.-U. Burger, A. Scherhag, and the CREATE Investigators Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia N. Engl. J. Med., November 16, 2006; 355(20): 2071 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Dworkin Controversial Treatment of Atherosclerotic Renal Vascular Disease: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions Trial Hypertension, September 1, 2006; 48(3): 350 - 356. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Sarafidis and G. L. Bakris Level of Kidney Function Determines Cardiovascular Fate After Coronary Bypass Graft Surgery Circulation, February 28, 2006; 113(8): 1046 - 1047. [Full Text] [PDF]
|
|